Your browser doesn't support javascript.
loading
Artificial intelligence for dementia genetics and omics.
Bettencourt, Conceicao; Skene, Nathan; Bandres-Ciga, Sara; Anderson, Emma; Winchester, Laura M; Foote, Isabelle F; Schwartzentruber, Jeremy; Botia, Juan A; Nalls, Mike; Singleton, Andrew; Schilder, Brian M; Humphrey, Jack; Marzi, Sarah J; Toomey, Christina E; Kleifat, Ahmad Al; Harshfield, Eric L; Garfield, Victoria; Sandor, Cynthia; Keat, Samuel; Tamburin, Stefano; Frigerio, Carlo Sala; Lourida, Ilianna; Ranson, Janice M; Llewellyn, David J.
Afiliação
  • Bettencourt C; Department of Neurodegenerative Disease, UCL Queen Square Institute of Neurology, London, UK.
  • Skene N; Queen Square Brain Bank for Neurological Disorders, UCL Queen Square Institute of Neurology, London, UK.
  • Bandres-Ciga S; UK Dementia Research Institute, Imperial College London, London, UK.
  • Anderson E; Department of Brain Sciences, Imperial College London, London, UK.
  • Winchester LM; Center for Alzheimer's and Related Dementias (CARD), National Institute on Aging and National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, Maryland, USA.
  • Foote IF; Department of Mental Health of Older People, Division of Psychiatry, University College London, London, UK.
  • Schwartzentruber J; Department of Psychiatry, University of Oxford, Oxford, UK.
  • Botia JA; Institute for Behavioral Genetics, University of Colorado Boulder, Boulder, Colorado, USA.
  • Nalls M; Open Targets, Cambridge, UK.
  • Singleton A; Wellcome Sanger Institute, Cambridge, UK.
  • Schilder BM; Illumina Artificial Intelligence Laboratory, Illumina Inc, Foster City, California, USA.
  • Humphrey J; Departamento de Ingeniería de la Información y las Comunicaciones, Universidad de Murcia, Murcia, Spain.
  • Marzi SJ; Center for Alzheimer's and Related Dementias (CARD), National Institute on Aging and National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, Maryland, USA.
  • Toomey CE; Data Tecnica International LLC, Washington, DC, USA.
  • Kleifat AA; Center for Alzheimer's and Related Dementias (CARD), National Institute on Aging and National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, Maryland, USA.
  • Harshfield EL; Laboratory of Neurogenetics, National Institute on Aging, National Institutes of Health, Bethesda, Maryland, USA.
  • Garfield V; UK Dementia Research Institute, Imperial College London, London, UK.
  • Sandor C; Department of Brain Sciences, Imperial College London, London, UK.
  • Keat S; Nash Family Department of Neuroscience and Friedman Brain Institute, Icahn School of Medicine at Mount Sinai, New York, USA.
  • Tamburin S; UK Dementia Research Institute, Imperial College London, London, UK.
  • Frigerio CS; Department of Brain Sciences, Imperial College London, London, UK.
  • Lourida I; Queen Square Brain Bank for Neurological Disorders, UCL Queen Square Institute of Neurology, London, UK.
  • Ranson JM; The Francis Crick Institute, London, UK.
  • Llewellyn DJ; Department of Basic and Clinical Neuroscience, Maurice Wohl Clinical Neuroscience Institute, Institute of Psychiatry, Psychology and Neuroscience, King's College London, London, UK.
Alzheimers Dement ; 19(12): 5905-5921, 2023 Dec.
Article em En | MEDLINE | ID: mdl-37606627
Genetics and omics studies of Alzheimer's disease and other dementia subtypes enhance our understanding of underlying mechanisms and pathways that can be targeted. We identified key remaining challenges: First, can we enhance genetic studies to address missing heritability? Can we identify reproducible omics signatures that differentiate between dementia subtypes? Can high-dimensional omics data identify improved biomarkers? How can genetics inform our understanding of causal status of dementia risk factors? And which biological processes are altered by dementia-related genetic variation? Artificial intelligence (AI) and machine learning approaches give us powerful new tools in helping us to tackle these challenges, and we review possible solutions and examples of best practice. However, their limitations also need to be considered, as well as the need for coordinated multidisciplinary research and diverse deeply phenotyped cohorts. Ultimately AI approaches improve our ability to interrogate genetics and omics data for precision dementia medicine. HIGHLIGHTS: We have identified five key challenges in dementia genetics and omics studies. AI can enable detection of undiscovered patterns in dementia genetics and omics data. Enhanced and more diverse genetics and omics datasets are still needed. Multidisciplinary collaborative efforts using AI can boost dementia research.
Assuntos
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Inteligência Artificial / Doença de Alzheimer Tipo de estudo: Guideline / Prognostic_studies / Risk_factors_studies Limite: Humans Idioma: En Ano de publicação: 2023 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Inteligência Artificial / Doença de Alzheimer Tipo de estudo: Guideline / Prognostic_studies / Risk_factors_studies Limite: Humans Idioma: En Ano de publicação: 2023 Tipo de documento: Article